Citigroup
VBIV

Citigroup’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Citigroup’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-147
Closed -$12K – 7618
2020
Q4 		$12K Buy
+147
New +$12.5K ﹤0.01% 6906

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's VBIV Position: Q1 2023 in Review

Citigroup sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 43 shares — an estimated $508 sold.

Citigroup first reported a position in VBIV in Q2 2017 and held it in 23 quarters. The position peaked at $3.94M in Q1 2021. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • Citigroup reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 43 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $508.
  • Citigroup first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 23 quarters.
  • Citigroup's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $3.94M in Q1 2021.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.